Acetyl-Leucine
Phase 3Small molecule
Acetyl-Leucine is one of 28 small molecule programs targeting Ataxia. It is currently in Phase 3.
1
Indications
1
Total Trials
1
Active Trials
27
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
34 competitors in Ataxia
#DrugCompanyPhaseTrials
1Rocaltrol
Alnylam PharmaceuticalsApproved
Plavix
SanofiPhase 3
Bayer Aspirin
BayerPhase 3
Actos
TakedaPhase 3
Diamox
TevaPhase 3
Chantix
PPrism Pharmaceuticals
Phase 3
Skyclarys
BiogenPhase 2
Epogen
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Phase 2
Ferriprox
Chiesi Farmaceutici S.p.A.Phase 2
Decadron
AAspen Global Incorporated
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Acetyl-Leucine. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- KKafrelsheikh University